Brokerages Set Vivos Therapeutics, Inc. (NASDAQ:VVOS) PT at $4.92

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) have earned an average rating of “Hold” from the five analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $4.9167.

Several equities analysts recently commented on the company. Zacks Research upgraded Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, December 1st. HC Wainwright began coverage on Vivos Therapeutics in a report on Monday, November 17th. They set a “buy” rating and a $7.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Wednesday, January 21st. Finally, Ascendiant Capital Markets lowered their target price on shares of Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating on the stock in a research note on Wednesday, December 3rd.

Institutional Investors Weigh In On Vivos Therapeutics

Several hedge funds have recently added to or reduced their stakes in VVOS. Connective Capital Management LLC purchased a new position in shares of Vivos Therapeutics in the 3rd quarter worth about $620,000. B. Riley Wealth Advisors Inc. bought a new stake in Vivos Therapeutics in the 2nd quarter worth approximately $220,000. Finally, XTX Topco Ltd bought a new stake in Vivos Therapeutics in the 2nd quarter worth approximately $65,000. Institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Stock Performance

NASDAQ VVOS opened at $1.50 on Friday. Vivos Therapeutics has a 1 year low of $1.42 and a 1 year high of $7.95. The company has a debt-to-equity ratio of 3.31, a current ratio of 0.78 and a quick ratio of 0.78. The stock has a market capitalization of $14.16 million, a PE ratio of -0.85 and a beta of 6.93. The company’s 50 day simple moving average is $2.02 and its two-hundred day simple moving average is $3.03.

Vivos Therapeutics (NASDAQ:VVOS) last released its quarterly earnings results on Wednesday, November 19th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. The firm had revenue of $6.78 million during the quarter, compared to analyst estimates of $4.49 million. Vivos Therapeutics had a negative net margin of 98.77% and a negative return on equity of 351.28%. Analysts predict that Vivos Therapeutics will post -1.79 earnings per share for the current fiscal year.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.